Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,088, titled ...
Years of legal battles have culminated in a decisive judgment against a well-known Toronto plastic surgeon, Dr. Martin Jugenburg. The ruling follows a comprehensive five-week common issues trial that ...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032 (the "Notes") ...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032 (the “Notes”) ...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced its intention to offer, subject to market and other conditions, $400 million aggregate principal amount of convertible senior notes due 2032 ...
For the first quarter of 2026, the Nomura Small Cap Core Fund Institutional shares underperformed the Russell 2000 Index, ...
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
Travere Therapeutics missed EPS and revenue forecasts for Q1 2026. Stock price increased by 1.81% in aftermarket trading. Filspari sales showed strong year-over-year growth. The company achieved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results